372 related articles for article (PubMed ID: 11304767)
1. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
Byrd JC; Murphy T; Howard RS; Lucas MS; Goodrich A; Park K; Pearson M; Waselenko JK; Ling G; Grever MR; Grillo-Lopez AJ; Rosenberg J; Kunkel L; Flinn IW
J Clin Oncol; 2001 Apr; 19(8):2153-64. PubMed ID: 11304767
[TBL] [Abstract][Full Text] [Related]
2. Rituximab dose-escalation trial in chronic lymphocytic leukemia.
O'Brien SM; Kantarjian H; Thomas DA; Giles FJ; Freireich EJ; Cortes J; Lerner S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2165-70. PubMed ID: 11304768
[TBL] [Abstract][Full Text] [Related]
3. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
[TBL] [Abstract][Full Text] [Related]
4. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
5. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Woyach JA; Lin TS; Lucas MS; Heerema N; Moran ME; Cheney C; Lucas DM; Wei L; Caligiuri MA; Byrd JC
Leukemia; 2009 May; 23(5):912-8. PubMed ID: 19225537
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
Faderl S; Ferrajoli A; Wierda W; O'Brien S; Lerner S; Keating MJ
Cancer; 2010 May; 116(10):2360-5. PubMed ID: 20225334
[TBL] [Abstract][Full Text] [Related]
9. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
Winkler U; Jensen M; Manzke O; Schulz H; Diehl V; Engert A
Blood; 1999 Oct; 94(7):2217-24. PubMed ID: 10498591
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
11. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
Williams ME; Densmore JJ; Pawluczkowycz AW; Beum PV; Kennedy AD; Lindorfer MA; Hamil SH; Eggleton JC; Taylor RP
J Immunol; 2006 Nov; 177(10):7435-43. PubMed ID: 17082663
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in chronic lymphocytic leukemia.
Jaglowski SM; Byrd JC
Semin Hematol; 2010 Apr; 47(2):156-69. PubMed ID: 20350663
[TBL] [Abstract][Full Text] [Related]
13. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study.
Itälä M; Geisler CH; Kimby E; Juvonen E; Tjonnfjord G; Karlsson K; Remes K
Eur J Haematol; 2002 Sep; 69(3):129-34. PubMed ID: 12406005
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in chronic lymphocytic leukemia.
Montserrat E
Semin Oncol; 2003 Feb; 30(1 Suppl 2):34-9. PubMed ID: 12652463
[TBL] [Abstract][Full Text] [Related]
16. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
Byrd JC; Waselenko JK; Maneatis TJ; Murphy T; Ward FT; Monahan BP; Sipe MA; Donegan S; White CA
J Clin Oncol; 1999 Mar; 17(3):791-5. PubMed ID: 10071268
[TBL] [Abstract][Full Text] [Related]
17. High-dose rituximab therapy in chronic lymphocytic leukemia.
Keating M; O'Brien S
Semin Oncol; 2000 Dec; 27(6 Suppl 12):86-90. PubMed ID: 11226005
[TBL] [Abstract][Full Text] [Related]
18. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Brown JR; Messmer B; Werner L; Davids MS; Mikler E; Supko JG; Fisher DC; LaCasce AS; Armand P; Jacobsen E; Dalton V; Tesar B; Fernandes SM; McDonough S; Ritz J; Rassenti L; Kipps TJ; Neuberg D; Freedman AS
Haematologica; 2013 Jun; 98(6):964-70. PubMed ID: 23645694
[TBL] [Abstract][Full Text] [Related]
20. Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients.
Ladetto M; Bergui L; Ricca I; Campana S; Pileri A; Tarella C
Med Oncol; 2000 Aug; 17(3):203-10. PubMed ID: 10962531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
